Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer

Endocrine-Related Cancer

Volumn 8, Issue 3, 2001, Pages 175-182

  Nicholson, R I ^a   Hutcheson, I R ^a   Harper, M E ^a   Knowlden, J M ^a   Barrow, D ^a   McClelland, R A ^a   Jones, H E ^a   Wakeling, A E ^a   Gee, J M W ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; FULVESTRANT; GEFITINIB; GROWTH FACTOR; ONCOPROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TRASTUZUMAB;

BREAST CARCINOMA; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER PREVENTION; CELL STRAIN MCF 7; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; HORMONE RESISTANCE; HORMONE RESPONSE; HUMAN; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR BINDING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0034790009     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0080175     Document Type: Conference Paper

References (73)

1. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo
2. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosinemonophosphate, and insulin-like growth factor-I
3. Clinical trials of Herceptin (trastuzumab)
4. D1839 ('Iressa') as an anticancer agent
5. Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: Its regulation by estrogen and its possible functional significance
6. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
7. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation
8. Predictors of response to second-line endocrine therapy for breast cancer
9. Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: A comparison of the effects of cyclic adenosine 3′, 5′-monophosphate, estradiol, insulin-like growth factor-I, and serum factors
10. Mechanisms of EGF receptor regulation in breast cancer cells
11. Antitumour effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
12. The effects of a constitutive expression of transforming growth factor-alpha on the growth of MCF-7 human breast cancer cells in vitro and in vivo
13. Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells
14. Inhibition of c-erbB2 oncogene expression by oestrogens in human breast cancer cells
15. Antiestrogen ICI 164384 reduces cellular estrogen receptor content by increasing its turnover
16. The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components
17. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study
18. New insights into the control of MAP kinase pathways
19. Antisense estrogen receptor RNA expression increases epidermal growth factor receptor gene expression in breast cancer cells
20. Mechanisms of 4-hydroxytamoxifen anti-growth factor activity in breast cancer cells: Alterations of growth factor receptor binding sites and tyrosine kinase activity
21. Phosphorylation of erk 1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer
22. Clinical response and resistance to SERMS
23. The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue
24. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells
25. The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue
26. Over-expression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
27. Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells
28. Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors
29. New EGF-R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC-3 and DU-145
30. Effects of EGF-R selective tyrosine kinase inhibitor and anti-androgen on LNCaP cells
31. Inhibition of HER/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-over-expressing, tamoxifen resistant breast cancer cells
32. Resistance of human breast cancer cells to the pure steroidal anti-estrogen ICI 182780 is not associated with a general loss of estrogen receptor expression or lack of estrogen responsiveness
33. Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells
34. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint
35. Enhanced epidermal growth factor receptor signalling in MCF-7 breast cancer cells after long-term culture in the presence of the pure antioestrogen ICI 182,780 (Faslodex)
36. Epidermal growth factor-related peptides and their cognate receptors in breast cancer
37. ZD 1839 'Iressa'
38. Emergence of MCF-7 cells over-expressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: Evidence for a role of EGFR in breast cancer growth and progression
39. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression
40. Growth factors and modulation of endocrine response in breast cancer
41. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer
42. New anti-hormonal approaches to breast cancer therapy
43. Relationship between EGF-R, c-erbB2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity
44. Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy
45. Transforming growth factor-alpha and endocrine sensitivity in breast cancer
46. Observations arising from the use of pure antioestrogens on oestrogen-responsive (MCF-7) and oestrogen growth-independent (K3) human breast cancer cells
47. Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896
48. erbB signalling in clinical breast cancer: Relationship to endocrine sensitivity
49. erbB signalling and endocrine sensitivity of human breast cancer
50. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells
51. The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients
52. Estradiol stimulates tyrosine phosphorylation of the insulin-like growth factor-1 receptor and insulin receptor substrate-1 in the uterus
53. Oestrogen receptor - A stable phenotype in breast cancer
54. Cellular effects of tamoxifen in primary breast cancer
55. Epidermal growth factor receptors on human breast cancers
56. Molecular mechanisms of antioestrogen action
57. Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer
58. A dual immunocytochemical assay for oestrogen and epidermal growth factor receptors in tumour cell lines
59. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
60. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
61. Cross-talk between peptide growth factor and estrogen receptor signaling pathways
62. Function of the IGF-I receptor in breast cancer
63. Over-expression of the epidermal growth factor receptor in human breast cancer cells fails to induce an estrogen-independent phenotype
64. Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells
65. Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations
66. Expression of receptors for epidermal growth factor and insulin-like growth factor I by ZR-75-1 human breast cancer cell variants is inversely related: The effect of steroid hormones on insulin-like growth factor I receptor expression
67. A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo
68. Inhibition of EGF receptor tyrosine kinase activity by 4-aniloquinazolines
69. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-aniloquinazolines
70. Basic fibroblast growth factor downregulates Bcl-2 and promotes apoptosis in MCF-7 human breast cancer cells
71. Estrogen suppression of erbB2 expression is associated with increased growth rate of ZR-75-1 human breast cancer cells in vitro and in nude mice
72. Bimodal regulation of epidermal growth factor receptor by estrogen in breast cancer cells
73. The role of estrogen in the regulation of EGFR expression